Previous studies have shown that patients with type 2 diabetes have increased levels of long-chain acylcarnitines, which can activate proinflammatory signaling pathways such as COX2, JNK, and ERK pathways, which can increase inflammatory processes [64]. Here, MAPK8 is linked to type 2 diabetes mellitus.